

Sepsis-Induced Endothelial Dysfunction: Permeability and Regulated Cell Death

Wei Zhang^{1,*}, Luofeng Jiang^{1,*}, Xirui Tong^{1,*}, Heng He^{1,*}, Yongjun Zheng¹, Zhaofan Xia^{1,2}

¹Department of Burn Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, 200433, People's Republic of China; ²Research Unit of Key Techniques for Treatment of burns and Combined Burns and Trauma Injury, Chinese Academy of Medical Sciences, Shanghai, 200433, People's Republic of China

*These authors contributed equally to this work

Correspondence: Zhaofan Xia; Yongjun Zheng, Department of Burn Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, 200433, People's Republic of China, Email xiazhaofan_smmu@163.com; smmuzhengyongjun@163.com

Abstract: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Endothelial cells (ECs) are an important cell type typically affected in sepsis, resulting in compromised barrier function and various forms of regulated cell death (RCD). However, the precise mechanisms underlying sepsis-induced EC damage remain unclear. This review summarizes the recent research progress on factors and mechanisms that may affect the permeability and RCD of ECs under septic conditions, including glycocalyx, damage-associated molecular patterns, and various forms of RCD in ECs, such as apoptosis, pyroptosis, ferroptosis, and autophagy. This review offers important insights into the underlying mechanisms of endothelial dysfunction in sepsis, aiming to contribute to developing small-molecule targeted clinical therapies.

Keywords: damage-associated protein, endothelial cell, glycocalyx, permeability, regulated cell death, sepsis


Introduction

As outlined in the most recent international consensus, sepsis is a severe organ dysfunction that continues to pose a significant threat to public health.¹ In 2017, an estimated 48.9 million cases and 11 million sepsis-related fatalities worldwide were documented, constituting roughly 20% of the annual global mortality.² The damage and dysfunction of vascular endothelial cells (ECs) are the shared characteristics in systemic reactions caused by sepsis.

Under physiological conditions, the extensive microvessels in the alveoli facilitate effective gas exchange. Meanwhile, ECs establish a semi-permeable membrane barrier that regulates the passage of fluids, proteins, and cells into tissues, thus maintaining the microvascular bed in an anti-thrombotic and anti-inflammatory state.³ However, during infections, including bacterial, fungal, or viral infections, both exogenous pathogen-associated molecular patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs) can induce overactivation of ECs, impair vascular integrity and barrier function, leading to increased permeability, interstitial edema, and other serious disruptions to gas exchange.³ Impaired EC function in vital organs can be particularly fatal. The lungs are the most susceptible target organ in cases of sepsis. This can result in the development of acute lung injury (ALI) and even acute respiratory distress syndrome (ARDS) finally.⁴ Similarly, EC damage and dysfunction can lead to damage to other vital organs, such as acute liver injury,⁵ acute kidney injury (AKI),⁶ encephalopathy,⁷ and disseminated intravascular coagulation (DIC).⁸ Thus, it is particularly important to analyze the specific mechanisms by which EC dysfunction occurs under septic conditions.

This review summarizes the recent research progress on factors and mechanisms that may affect the permeability and regulated cell death (RCD) of ECs under septic conditions, including glycocalyx, DAMPs, and various forms of RCD in ECs, such as apoptosis, pyroptosis, ferroptosis, and autophagy. This review offers important insights into the underlying mechanisms of endothelial dysfunction in sepsis, aiming to contribute to developing small-molecule targeted clinical therapies.

Graphical Abstract



GCX

The GCX is a large molecular substance that attaches to the luminal surface of ECs. Initially identified in 1966 via ruthenium red staining by Luft and his team,⁹ the GCX comprises sulfated proteoglycans (including syndecans and glypicans), glycosaminoglycans (such as hyaluronic acid [HA], heparan sulfate [HS], and chondroitin sulfate), and sialic acid proteins.^{10,11} In addition to the well-researched cell–cell junction, the GCX plays a crucial role in maintaining barrier function.¹² It can respond to shear stress sensed in the bloodstream by modulating vasoconstriction via the regulation of nitric oxide (NO), a biologically important inorganic compound that facilitates vasodilation and controls vascular tone.^{13,14} Initially, the GCX was perceived as a physical barrier that separates the blood from ECs, and its impact on EC water permeability was the primary focus.¹⁵ Recently, clinical studies have revealed that GCX degradation and shedding are prevalent in patients with sepsis or severe trauma, particularly in individuals with low plasma colloid osmolality.^{16,17}

The mechanisms associated with GCX degradation are complex. The classical theory suggests that pro-inflammatory factors, such as tumor necrosis factor- α (TNF- α) and interleukin-1 β (IL-1 β), activate specific enzymes, such as metalloproteinase, heparanase (HPSE), and hyaluronidase, resulting in GCX degradation.^{16,18} The pathophysiology of GCX damage may be attributed to the involvement of a disintegrin and metalloproteinase 15 (ADAM15), a membrane-bound metzincin metalloproteinase implicated in GCX shedding and vascular penetration in sepsis.¹⁹ This process may involve the degradation of the GCX protein, CD44, on the EC membrane, resulting in the disruption of the VE-cadherin- β -catenin complex and compromised cell–cell adhesion.¹⁹ Additionally, ADAM15 facilitates neutrophil transmigration across cell membranes. Thus, ECs may be further placed in an inflammatory microenvironment.¹⁹ Recent in vitro experiments have further supported the association between the GCX and vascular permeability.^{20–22} For example, during sepsis, GCX shedding and degradation are closely linked to thrombin depletion. This phenomenon might be caused by the loss of HA and syndecan-1 (SDC-1) and the heightened EC permeability resulting from concurrent catecholamine responses.^{20,21} Moreover, increases in the plasma levels of free SDC-1, which is released upon GCX damage, predict adverse outcomes.^{23,24} In the clinical setting, sepsis induces significant changes in polysaccharide metabolism, and different EC subtypes exhibit similar metabolic characteristics with a significant upregulation of glycan and fatty acid metabolisms. GCX shedding is also more evident in patients with reduced colloid osmotic pressure.^{25,26}

The analysis of publicly available serum metabolomic data from patients with septic shock revealed significant changes in glycan metabolism among non-survivors.^{25,26} One clinical trial reported an increase in the translation of HPSE and the expression of its active form during sepsis, which was associated with sepsis-related mortality.²⁷ HPSE is the only known endoglycosidase in mammals that can degrade HS, which is a major component of the GCX.²⁸ Heparin inhibits the cytosolic delivery of lipopolysaccharide (LPS) via the prevention of HPSE-mediated GCX degradation. Therefore, using heparin in the treatment of sepsis can improve the prognosis through anticoagulation and protect ECs by inhibiting HPSE.^{29,30} However, the mechanisms that affect the structural integrity of the GCX on ECs require further investigation.

The specific manifestations of the effect of GCX damage on the EC barrier function have also been investigated. Reliable experimental data have indicated that the GCX increases vascular permeability and promotes leukocyte adhesion following injury.²² However, distinguishing between EC connectivity and the GCX in terms of vascular permeability is challenging.³¹ Under septic conditions, GCX degradation forms a vicious cycle. For example, the GCX plays an important role in EC homeostasis, while GCX degradation reduces the bioavailability of NO, which is closely related to the increase in reactive oxygen species (ROS) (Figure 1).^{32,33} Consequently, increased ROS activates various specific enzymes (such as metalloproteinase, HPSE, and hyaluronidase) that destroy the GCX structure³⁴ and cause ECs to transform into myofibroblasts.³⁵ Damage to the GCX structure further affects the expressions of tight junction (TJ) proteins, thereby impairing barrier function.³⁶ HPSE can selectively strip HS from GCX to form the HPSE–HS complex, interfering with the synthesis of the TJ protein, zona occludens-1 (ZO-1).³⁶ Additionally, HPSE can impact the integrity of the GCX and interfere with the expression of *ZO-1* mRNA, subsequently affecting the assembly and function of TJ proteins. These effects can be counteracted by *N*-desulfated/*re*-*N*-acetylated heparin, which may be effective in protecting the GCX.^{36,37}

Neutrophils participate in intrinsic immunity and typically play a role in the phagocytosis of fine microorganisms in infectious diseases such as sepsis. Their numbers are commonly clinically indicative of the degree of infection or inflammation. Golden and his team proposed a mechanism of HS-dependent neutrophil enrichment in the liver.³⁸ In a mouse model of *Staphylococcus aureus*-induced septicemia, rapid remodeling of the protein composition on the surface




Figure 1 Schematic illustration of the vicious cycle that occurs when the GCX breaks down. First, sepsis functions as an initiating factor to destroy the GCX. Subsequently, ROS levels increase. Finally, specific enzymes are activated to decompose the GCX, completing the closed loop. Created in BioRender. Jiang, L. (2024) <http://BioRender.com/w57v515>.

of hepatic blood vessels was observed. These changes included the deposition of proteins from neutrophils (such as myeloperoxidase, neutrophil elastase, matrix metalloproteinase 9, and neutrophil gelatinase-associated lipocalin) and alterations in the levels of HS-binding factors that occurred before the onset of liver injury.³⁸ Their study on sepsis-related liver failure has provided experimental evidence that the genetic modification of fine HS structures can reduce the transport of neutrophils to the liver^{39,40} and that the modulation of vascular GCX can reduce neutrophil infiltration in aseptic liver injury.³⁸ Although further research is required, elevated levels of plasma-derived GCX fragments (HS or HA) can be used to predict adverse outcomes in sepsis, potentially involving HS-dependent neutrophil enrichment.^{23,24,38} Empagliflozin reduces the inflammatory state of the endothelium caused by GCX degradation; however, this mechanism may be independent of HS. Empagliflozin can reduce the activation of nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3 (NLRP3) by downregulating pro-apoptotic signals and the thioredoxin-interacting protein, thereby reducing oxidative damage from endoplasmic reticulum (ER) stress.^{41,42} Thus, protecting the GCX from being shed or removing GCX breakdown products may help to relieve EC dysfunction and protect blood vessels during sepsis.

DAMPs

In the mid-1990s, Polly Matzinger introduced the concept of DAMPs, which are endogenous molecules extracellularly released following tissue injury that activate pro-inflammatory cascade responses and play a crucial role in sepsis.⁴³ Various potential DAMPs, such as ATP, high mobility group box 1 (HMGB1), extracellular chromosomal DNA, mitochondrial DNA, histones, and heme, participate in the development of sepsis injury. Among them, HMGB1, histones, and heme have been more widely studied;⁴⁴⁻⁴⁷ therefore, we summarize the related research progress as follows.

HMGB1

As a nuclear factor and secreted protein, HMGB1 exhibits a high degree of conservation, with 99% homology between human and rodent species.⁴⁸ HMGB1 can exist in the nucleus and extracellular matrix. Within the nucleus, HMGB1 normally functions as a chromatin-binding factor, aiding in the assembly of proteins on specific DNA targets and inducing DNA bending.⁴⁴ However, HMGB1 exhibits a weak binding affinity to chromatin and is rapidly released into the extracellular environment upon cell damage.⁴⁹

HMGB1 has multiple deleterious on endothelial cell function. During sepsis, HMGB1 is passively released owing to intense inflammation or cytolytic necrosis, particularly in cells undergoing mitosis or those in interphase. Type 1 interferon-mediate signaling can induce the release of HMGB1 in macrophages and monocytes.⁵⁰ Moreover, lactylation and acetylation modifications of HMGB1 facilitate its secretion from macrophages through exosomes.⁵¹ Extracellular HMGB1 interacts with LPS, a critical constituent of the outer membrane of gram-negative bacteria, to facilitate LPS internalization into ECs via endocytosis, thereby triggering caspase-11-dependent pyroptosis.⁵² HMGB1 can also bind to LPS, mediating its transport to macrophages during sepsis. This process activates caspase-11 and caspase-1 signaling, which triggers apoptosis, autophagy, and pyroptosis (Figure 2).⁴⁹ Moreover, HMGB1 increases the procoagulant activity of tissue factors and promotes the exposure of procoagulant phosphatidylserine on the cell surface. This contributes to the assembly of prothrombin complexes and ultimately results in widespread DIC.⁵⁰

At the same time, HMGB1 has multiple beneficial effects on endothelial cell function. HMGB1 can promote mitochondrial fusion in ECs via the C-X-C-chemokine receptor 4 (CXCR4) /20S proteasome subunit beta 5 pathway without significantly affecting their inflammatory phenotype.⁵³ The current view is that proper mitochondrial fusion facilitates the maintenance of normal mitochondrial and cellular functions and supports increased energy metabolism during cell proliferation.^{54,55} HMGB1 may also play a regulatory role in angiogenesis. The internalization of HMGB1 via the receptor for advanced glycation end-products (RAGE) located on the cellular membrane could induce the secretion of vascular endothelial growth factor-A and endoglin.⁵⁶ This process is facilitated by the release of fragments from a crucial functional domain of HMGB1, which occurs owing to cytokine activity. Notably, in vivo experiments conducted on mice demonstrated that this phenomenon promotes angiogenesis in ligated femoral arteries.⁵⁶ Thus, these findings provided new insights into the mechanism underlying HMGB1-mediated cytoprotective effects and revealed that HMGB1 may exhibit a specific double-edged sword effect on ECs.

Histones

Histones are evolutionarily conserved nuclear proteins that interact with DNA to create nucleosomes. In particular, the histone subunits H1B, H2A, H2B, H3, and H4 play crucial roles in chromatin compaction and chromosomal structure formation.⁵⁷ In the instances of severe trauma or infections such as sepsis, extracellular DNA-binding proteins, such as histones, can trigger immune responses and vascular dysfunction in the host.^{47,58} Histones are released either passively as DAMPs during cell necrosis or actively by neutrophils as part of neutrophil extracellular traps, which contain histones, myeloperoxidase, and extracellular DNA.^{43,59} At present, circulating histones are considered as the primary mediators of cell death and multiple organ dysfunction in sepsis.^{60–62} Furthermore, the administration of anti-histone antibodies in different animal models of sepsis resulted in reduced mortality rates.^{58,63} EC function impairment has since been confirmed to be primarily mediated by Toll-like receptor 4 (TLR4) signaling.^{64,65} A recent experimental study revealed that the levels of impact of the histone subunits H3 and H4 on EC permeability differed from those of the H2A and H2B subunits. H3 and H4 are responsible for damaging ECs, and an increase in ECs permeability can be observed even at low histone concentrations.⁴⁷ Once the histone concentration surpasses a certain threshold, the expression of EC adhesion molecules, such as intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1), is significantly increased.⁴⁷ Notably, both ICAM1 and VCAM1 belong to the immunoglobulin superfamily of cell adhesion molecules and are essential in facilitating the robust adhesion of leukocytes to ECs. Histones disrupt cellular junctions by phosphorylating the tight junction molecule, VE-cadherin, resulting in EC barrier dysfunction, increased permeability, and the upregulation of inflammatory responses (Figure 2).⁴⁷




Figure 2 Effect of DAMPs on vascular ECs during sepsis or severe bacterial infections. Right: Histones primarily function via the activation of related signaling pathways by TLR4 and can phosphorylate VE-cadherin to further weaken the tight junctions between ECs. Center: HMGB1 and LPS combine and enter cells via endocytosis and activate the caspase-1/11-related signaling pathway. Left: In ECs, heme promotes IL-1 β release by activating the NLRP3 inflammasome, resulting in an inflammatory response. Created in BioRender: Jiang, L. (2024) <http://BioRender.com/v55n286>.

Heme

Heme (iron protoporphyrin-IX) is a naturally occurring iron chelate synthesized by the mitochondria that is primarily involved in oxygen transport and storage and cellular metabolic enzyme activity.^{66–68} Increased circulating free heme levels have been linked to a higher risk of hemolytic disorders, such as sickle cell anemia, and regulated EC death in patients with severe sepsis.^{66,69} Moreover, the excessive release of free heme under pathological conditions is associated with EC barrier dysfunction. In macrophages, heme or the oxidized form of hemoglobin stimulates NLRP3, resulting in the production of the inflammatory factor IL-1 β .^{70,71} In ECs, heme, rather than hemoglobin, activates the NLRP3 inflammasome, resulting in the release of IL-1 β (Figure 2).⁴⁵ Heme oxygenase-1 (HO-1) can effectively degrade heme, converting it to carbon monoxide, iron, and biliverdin, and is beneficial and therapeutic for maintaining EC barrier function.^{72,73} Recently, MitoQ (a mitochondria-targeted antioxidant) was found to effectively reduce EC damage and inhibit endothelial apoptosis by suppressing the degradation of nuclear factor erythroid 2-related factor 2 (NRF2) and upregulating downstream HO-1.⁷⁴ Regarding the molecular mechanism by which heme affects EC barrier function, one study reported that following heme exposure, the levels of the TJ proteins, ZO-1, claudin-1, and claudin-5, were primarily reduced, while the p38 mitogen-activated protein kinase (MAPK)/heat shock protein 27 pathway, which mediates endothelial cytoskeleton changes, underwent significant alterations.⁷⁵ Notably, the MAPK family is activated by various environmental stress and inflammatory cytokines and the heat shock protein 27 is one of the downstream targets of p38 MAPK.⁷⁵ These conditions improved following the knockout of a key regulator, MKK3, suggesting that targeting this pathway may be a therapeutic strategy to mitigate sepsis and sepsis-related disorders.⁷⁵

The DAMPs discussed above are not independent entities; they interact with one another and collectively contribute to severe infections such as sepsis. As previously discussed, HMGB1 is a pivotal pro-inflammatory factor in sepsis; it can bind to DNA, RNA, nucleosomes, and histones, thereby participating in the inflammatory regulation response.⁷⁶ HMGB1 may also interact with histones, affecting their acetylation state.^{77,78} Similarly, HMGB1 can bind to the toll-like receptor 4 (TLR4) receptor to activate the innate immune response.⁷⁹ Heme, an important iron-containing compound in the human body, can induce the release of HMGB1 and produce a synergistic effect with it, both participating in the pathogenic mechanism of sepsis.⁶⁹ Notably, HMGB1 can affect enzymes involved in heme metabolism, such as HO-1, promoting ferroptosis in ECs.⁸⁰ These DAMPs, as part of the DAMP family, influence each other through various pathways and play a pro-inflammatory synergistic role in sepsis.

Oxidative Stress

Normally, cells themselves can produce oxidants such as ROS. The high oxidative stress environment of sepsis can impair the EC antioxidant function due to excessive consumption of antioxidants, such as glutathione, superoxide dismutase, and catalase, thus disrupting the balance between ROS, reactive nitrogen species, and antioxidants.³² Oxidative stress, a pathway associated with damage, can induce cell damage and even EC necrosis, which directly leads to the release of DAMPs.^{81,82} ROS relies on its strong oxidizing properties, oxidizing the lipid membrane of the cell, as well as the proteins, DNA and organelles within the cell.³² The ER exposed to oxidants could lead to ER stress and the release of vesicles containing HMGB1, thereby facilitating inflammation development.⁴² Similarly, DAMPs can be oxidatively modified, leading to inactivation of physiological functions and promoting pathology.⁸³

Meanwhile, the release of DAMPs could further aggravate tissue damage and inflammatory responses, exacerbates oxidative stress, leading to ROS production.⁸⁴ Upon increased ROS levels within the cell, HMGB1 shifts from its reduced form, which exhibits chemotactic activity, to its oxidized form with disulfide bonds, known as oxidized HMGB1 (Ox-HMGB1).⁸⁵ Extracellularly, Ox-HMGB1 with intramolecular disulfide bonds may have a stronger pro-inflammatory effect. Ox-HMGB1 binds more to TLR4, which activates immune cells more strongly and releases more inflammatory factors, exacerbating the inflammatory response and ROS production.⁸⁶ Notably, when intracellular levels of ROS exceed a certain threshold, two Ox-HMGB1 molecules can form disulfide bonds between cysteine residues, resulting in the production of an anti-parallel oxidative self-dimerized HMGB1 that confers protection to DNA.⁸⁵ In addition, free heme is detrimental and exacerbates oxidative stress in ECs, leading to cellular damage.⁸⁷ Heme can catalyze ROS production and oxidize proteins and lipids, leading to DNA damage.⁸⁸ Heme has a high affinity for biological membranes, rendering them susceptible to ROS and resulting in oxidative damage to membrane lipids.⁸⁹ It also activates the unfolded protein response pathway, leading to ER stress.⁹⁰ These results suggest the interaction between DAMPs and oxidative stress, and the regulation of DAMPs or oxidative stress level may contribute to the improvement of the inflammatory environment in sepsis.

RCD

Distinct from instantaneous and catastrophic cell death under physical or mechanical conditions, RCD is a form of cell death caused by intracellular events. It relies on precise molecular regulatory mechanisms and can be modulated by drugs or genetic intervention.^{91,92} In 2018, the Nomenclature Committee on Cell Death (NCCD) updated the classification of RCD by dividing it into 13 categories.⁹³ Through an extensive review of the literature, we found that increasing evidence indicates that EC apoptosis, pyroptosis, ferroptosis, and autophagy triggered by pathogenic components, such as LPS, inflammatory cytokines, and oxidative stress, are involved in multi-organ dysfunction and septic shock caused by sepsis. Here, we briefly discuss the specific mechanisms and targets of apoptosis, pyroptosis, ferroptosis, and autophagy in ECs during sepsis.

Apoptosis of ECs in Sepsis

Apoptosis is an active and orderly cell death process regulated by gene expression that aims to maintain cellular homeostasis under physiological or pathological conditions. Both *in vitro* and *in vivo* experiments have demonstrated that sepsis can induce EC injury and apoptosis, which is characterized by the formation of apoptotic bodies.⁹⁴⁻⁹⁶ We




Figure 3 Specific pathophysiological mechanisms of EC apoptosis in sepsis. Increased inflammation and oxidative stress and the activation of the NF- κ B signal pathway due to macrophage could aggravate EC apoptosis. Moreover, the ceRNA network comprising non-coding RNA could also regulate EC apoptosis. Created in BioRender. Jiang, L. (2024) <http://BioRender.com/k50n929>.

present the specific pathophysiological mechanisms of EC apoptosis in sepsis from three aspects: inflammation and oxidative stress, cellular communication, and non-coding RNA (Figure 3).

A highly inflammatory environment and elevated oxidative stress levels under septic conditions are the primary factors resulting in EC apoptosis, which involves complex molecular mechanisms. PD-L1 can activate the inflammatory response of pulmonary vascular ECs via the hypoxia-inducible factor-1 α (HIF-1 α) signaling pathway, thereby increasing apoptosis.⁹⁷ Inhibiting inflammation is considered a reliable way to protect against apoptosis. Research has indicated that interleukin-35, an anti-inflammatory cytokine, exerts anti-inflammatory and anti-apoptotic effects on LPS-induced ECs by activating the signal transducer and activator of transcription (STAT) 1 and 4 signaling pathways.⁹⁸ Another study used genome-wide CRISPR/Cas9 knockout screening technology to explore potential targets in the TNF- α signaling pathway using TNF- α -stimulated human umbilical vein endothelial cells (HUVECs). This study identified and confirmed NLR family member X1 (NLRX1) as a new regulatory factor involved in TNF- α -induced EC apoptosis.⁹⁹ Moreover, the regulatory role of Yes-associated protein (YAP) in EC apoptosis has been reported. As a key effector molecule of the Hippo signaling pathway, YAP participates in regulating various biological processes of cells, including proliferation, differentiation, transformation, and apoptosis. In human pulmonary microvascular endothelial cells (HPMECs), LPS can promote the phosphorylation of YAP on Y357, leading to its translocation from the cytoplasm to the nucleus, where it interacts with the transcription factor P73 to induce EC apoptosis. This suggests that YAP may serve as a potential therapeutic strategy for sepsis-induced lung injury.¹⁰⁰ Moreover, calpain and its signaling pathway also contribute to sepsis-induced EC injury. In LPS-induced AKI, the activation of endothelial calpain can promote p38 phosphorylation, increase the expression of inducible nitric oxide synthase (iNOS), and further enhance the excessive expression of NO and ROS, ultimately inducing EC apoptosis.¹⁰¹

ER stress is also involved in the apoptosis of ECs during sepsis, primarily through the oxidative stress-activated inositol requiring enzyme-1 α (IRE1 α) signaling pathway. This can be inhibited by adipocyte-secreted adiponectin, thereby reducing apoptosis in ECs.⁹⁶ Extracellular histones can function as DAMPs, inducing oxidative stress and dose-

dependently inducing apoptosis of primary HUVEC in a p53-Bax-dependent manner at concentrations of 50 µg/mL or higher.¹⁰² Moreover, in LPS-induced ECs, calpain activation and p38 MAPK phosphorylation are enhanced, resulting in apoptosis, whereas heat stress protects ECs by blocking these pathways.¹⁰³

Interactions between cells also play crucial roles in EC dysfunction and apoptosis. As a key immune cell type involved in septic conditions, macrophages exacerbate LPS-induced EC dysfunction and promote apoptosis by reducing angiopoietin-1 (Ang1) expression and activating the nuclear factor kappa-B (NF-κB) pathway.¹⁰⁴

Recent studies have demonstrated that non-coding RNAs, including long non-coding RNAs (lncRNAs), circular RNAs, and microRNAs (miRNAs), participate in regulating apoptosis in ECs under septic conditions, offering potential targets for sepsis treatment through competing endogenous RNA (ceRNA) regulatory networks. The lncRNA taurine-upregulated gene 1 (TUG1) can inhibit sepsis-induced inflammation and EC apoptosis by targeting miR-34b-5p and its downstream target gene *GRB2 associated binding protein 1 (GAB1)*¹⁰⁵ or miR-27a-3p and its downstream target gene *slit guidance ligand 2 (SLIT2)*.⁹⁵ Another study demonstrated the downregulation of lncRNA LUADT1 in plasma samples collected from patients with sepsis. This downregulation of LUADT1 has also been confirmed in LPS-stimulated human primary coronary artery ECs (HPCAECs). Further bioinformatics analysis, combined with experimental verification, indicated that LUADT1 can inhibit LPS-induced apoptosis of HPCAECs by sponging miR-195 and increasing the expression of the target gene *Pim-1*.¹⁰⁶ CircC3P1 exerts anti-inflammatory and anti-apoptotic effects on LPS-treated primary mouse lung microvascular ECs by targeting miR-21.¹⁰⁷ CircPALM2 inhibition regulates the miR-450b-5p/Rho-associated coiled-coil containing protein kinase 1 (ROCK1) axis to alleviate sepsis-induced apoptosis and inflammation in primary mouse lung microvascular ECs.¹⁰⁸ Individual miRNAs intrinsically regulate apoptosis in ECs. For example, miR-1-3p can target *stress-associated ER protein 1 (SERP1)*, inhibit EC proliferation, and promote apoptosis, thereby exacerbating EC dysfunction and promoting ALI development.¹⁰⁹ miR-297 reduces STAT3 expression, thereby alleviating LPS-induced inflammation and protecting ECs from apoptosis.¹¹⁰ The downregulation of miR-146a-5p can upregulate *neuropilin 2 (NRP2)* and *slingshot protein phosphatase 1 (SSHI)*, inhibit the expression of pro-inflammatory factors, and reduce LPS-induced EC apoptosis.¹¹¹ MiR-92a plays an important role in sepsis-induced ARDS. It promotes apoptosis in LPS-induced HPMECs by inhibiting the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway, thereby adversely affecting ARDS.¹¹² These studies provide effective targets against the apoptosis of ECs and the alleviation of EC dysfunction in sepsis, offering the potential for clinical translation.

Pyroptosis of ECs in Sepsis

Pyroptosis is one of the most important types of RCD associated with septic shock and tissue damage and is triggered by PAMPs, DAMPs, and inflammatory cytokines. The primary distinction between pyroptosis and apoptosis lies in the disruption of the cell plasma membrane integrity, resulting in the release of cell contents. This phenomenon amplifies local inflammatory responses and the early release of IL-1β and IL-18, which results in an imbalanced immune response and exacerbation of tissue damage.^{113,114} The specific pathophysiological mechanisms of EC pyroptosis in sepsis are illustrated from three aspects: GSDMD-NT dependent pathway, NLRP3 dependent pathway, and cellular communication (Figure 4).

Pyroptosis is an inflammatory form of cell death. First, LPS binds to the TLR4 co-receptor myeloid differentiation protein-2 (MD2) complex on the cell membrane. The LPS then activates caspase-11, which cleaves gasdermin D (GSDMD) to release its N-terminal fragment (GSDMD-NT), forming a transmembrane pore and inducing GSDMD-dependent pyroptosis.^{115–118} Furthermore, the GSDMD-dependent pyroptotic pathway participates in a novel mitochondrial mechanism. The LPS-induced GSDMD-NT can bind to the mitochondrial membrane and form mitochondrial pores, causing mitochondrial damage and subsequent mitochondrial DNA release into the cytosol. This is accompanied by the activation of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway and the suppression of YAP-mediated EC proliferation and vascular regeneration.¹¹⁹ A recent study also discovered a calcium-dependent mechanism in GSDMD-mediated pyroptosis, in which cytosolic calcium signaling promoted the translocation of the NH₂-terminal fragment of GSDMD-NT to the plasma membrane, enhancing endothelial pyroptosis. Phospholipase Cγ1 can also induce endothelial barrier dysfunction via this pathway, exacerbating perfusion impairment and increasing mortality in mice with sepsis.¹²⁰ In addition, PTMs of GSDMD may offer a potential approach for treating sepsis-




Figure 4 Potential mechanisms of EC pyroptosis in sepsis. The GSDMD-NT-dependent pathway participates in activating pyroptosis by inducing the formation of transmembrane pores and mitochondrial damage, which further promotes pyroptosis. The NLRP3-dependent pathway is important in pyroptosis occurrence, and several DAMPs, such as extracellular histones and eCIRP, and complement C3a can increase NLRP3 levels. Recent research has demonstrated that Group 2 innate lymphoid cells (ILC2), hepatocytes, and macrophage can regulate pyroptosis by influencing caspase family proteins or NLRP3. Created in BioRender: Jiang, L. (2024) <http://BioRender.com/b96h492>.

induced EC injury. Notably, O-linked β -N-acetylglucosamine (O-GlcNAc) modification of GSDMD can reduce LPS-induced EC pyroptosis by inhibiting the interaction between LPS and caspase-11.¹²¹

The NLRP3 inflammasome plays a critical role in the initiation and development of endothelial pyroptosis. Extracellular histones function as DAMPs, activating the NLRP3 inflammasome and mediating endothelial pyroptosis. The high acetylation of extracellular histones or the use of antioxidants can significantly reduce pyroptosis, suggesting that blocking histone-mediated pyroptosis is a feasible therapeutic strategy against sepsis.¹²² Extracellular cold-inducible RNA-binding protein (eCIRP) is a DAMP with a significant impact on the pathophysiology of inflammatory diseases. In ECs, eCIRP can induce NLRP3 inflammasome activation via the TLR4/MD2 and NF- κ B-dependent pathways, increase ICAM1 expression, activate the inflammatory response, and subsequently induce caspase-1, IL-1 β , and IL-18 expressions, leading to pyroptosis.^{123,124} Blocking NLRP3-mediated inflammation through drug intervention is an effective approach for inhibiting pyroptosis. Astragaloside IV can alleviate LPS-induced endothelial pyroptosis by inhibiting the ROS/NLRP3-mediated inflammatory response, providing a scientific basis for its clinical application.¹²⁵ Notably, some studies have suggested that genetic factors can affect the severity of sepsis. For example, in the Chinese Han population, individuals with a high genetic copy number of *DEFA1/DEFA3* genes, which encode human neutrophil peptides (HNP) 1–3, are more likely to develop severe sepsis.¹²⁶ Another study indicated that HNP-1 can mediate the activation of the canonical NLRP3/caspase-1 inflammasome through its interaction with the purinergic receptor P2X ligand-gated ion

channel 7 (P2X7), subsequently inducing pyroptosis of ECs and playing an important role in sepsis-induced EC injury and organ dysfunction.¹²⁷

The complement system is an essential part of host defense mechanisms and promotes inflammation by activating leukocytes and ECs. The complement pathway also plays a crucial role in promoting pyroptosis during sepsis.^{128,129} Complement C3 is at the core of the complement activation pathway. C3a levels in organs affected by sepsis are significantly elevated and are closely correlated with sepsis-related organ dysfunction and poor prognosis. Further investigations into the role and mechanism of C3a in sepsis-induced ALI have revealed that C3a binds to the C3a receptor, subsequently activating the NLRP3/caspase-1 and caspase-11 signaling pathways, resulting in pyroptosis in pulmonary vascular ECs.¹³⁰

Various cells are also widely involved in the regulation of EC pyroptosis. Group 2 innate lymphoid cells (ILC2) are one of the three subgroups of innate lymphoid cells (ILC1, ILC2, and ILC3) and are the primary ILC population in the lungs. The release of IL-33 during sepsis can induce the expansion of ILC2 in the lungs via its receptor suppression of tumorigenicity 2 (ST2), and the expanded ILC2 can secrete IL-9, which inhibits caspase-1 activation, thereby preventing pyroptosis in pulmonary ECs.¹³¹ Hepatocytes can sense PAMPs in circulation and release HMGB1. HMGB1 then forms complexes with LPS and enters EC lysosomes via the RAGE, causing lysosomal instability and enabling LPS to enter the cytoplasm. Subsequently, caspase-11 is activated, resulting in EC pyroptosis.⁵² Heparin or non-anticoagulant-modified heparin can inhibit the interaction between HMGB1 and LPS, minimizing the entry of LPS into the cytoplasm, and blocking caspase-11 activation while reducing pyroptosis.¹³² This may represent a potential therapy to alleviate ALI. In addition, exosomes with low miR-141 expression derived from macrophages can activate the downstream target NLRP3 and mediate pyroptosis of ECs, thereby promoting the progression of sepsis;¹³³ this represents a potentially valuable target for the treatment of sepsis.

Ferroptosis of ECs in Sepsis

Ferroptosis, a newly recognized form of unique cell death, is driven by iron-dependent lipid peroxidation and regulated by various cellular metabolic pathways and signaling cascades.^{134,135} Notably, ferroptosis is prevalent in sepsis and may contribute to the development of multi-organ dysfunction syndrome.¹³⁶ In this section, the relevant progress of ferroptosis of ECs under septic conditions will be comprehensively discussed (Figure 5).

Metabolomic analysis has revealed that sepsis induces ferroptosis in vascular ECs, leading to elevated lipid peroxidation.¹³⁷ Recent studies have reported that glutathione peroxidase 4 (GPX4) and NRF2 are the primary factors involved in ferroptosis regulation, with GPX4 serving as an antioxidant enzyme that reduces lipid peroxidation and negatively modulates ferroptosis.^{138,139} NRF2 is a crucial transcription factor that plays a pivotal role in regulating various cytoprotective genes, including *GPX4*.¹⁴⁰ Therefore, interventions targeting GPX4 and NRF2 may serve as effective approaches to ameliorate the ferroptosis of ECs in sepsis. In addition, research teams have confirmed that dexmedetomidine enhances EC resilience against ferroptosis in sepsis by upregulating the NRF2 signaling pathway, suppressing mitochondrial fission, and promoting metabolic reprogramming. Dex treatment reinforces cell–cell connections and improves barrier function, offering protective effects against sepsis-induced organ dysfunction.¹³⁷ The membrane protein six transmembrane epithelial antigen of the prostate 1 (STEAP1), which plays a pivotal role in cell adhesion and communication, has been implicated in ferroptosis. A sepsis-induced ALI model was used to demonstrate that STEAP1 expression was upregulated under septic conditions, and its inhibition reduced ROS production and inflammatory levels. Additionally, STEAP1 inhibition upregulated NRF2 expression, thereby attenuating EC ferroptosis, which may be mediated by the solute carrier family 7 member 11/GPX4 axis.¹⁴¹

In addition, the mutual regulation between cells is crucial for EC ferroptosis. Extracellular vesicles secreted by adipose-derived stem cells (ADSCs) can attenuate ferroptosis in sepsis-induced pulmonary microvascular ECs. Mechanistic experiments have confirmed that ADSC-derived extracellular vesicles specifically delivered miR-125b-5p to inhibit the target gene *kelch-like ECH-associated protein-1 (KEAP1)*, resulting in increased expression of *NRF2* and *GPX4*. This process reduces oxidative stress levels in lung tissues and mitigates EC ferroptosis, thereby alleviating tissue damage.¹⁴² Neutrophil extracellular traps (NETs) secreted by neutrophils play an important role in ALI. The component neutrophil elastase is significantly increased in the plasma of patients with sepsis. Moreover, NETs can induce damage in




Figure 5 Overview of the mechanisms related to ferroptosis of ECs in sepsis. NRF2 and GPX4 act as the key proteins in ferroptosis. Exosomes derived from ADSCs, rich in miR-125-5p, can influence the expression of NRF2, alleviating ferroptosis. Dexmedetomidine and STEAP1 can also regulate ferroptosis via NRF2. NETs may promote ferroptosis by blocking the formation of the SDC-1/HS complex and interfering with the cMET signaling pathway. Moreover, circEXOC5 can recruit IGF2BP2 to induce the degradation of *ATF3* mRNA, inducing EC ferroptosis. GDF11 can inhibit ferroptosis by activating the SIRT1/NOX4 pathway. Created in BioRender: Jiang, L. (2024) <http://BioRender.com/p37f510>.

the glycocalyx of ECs, disrupting the formation of the SDC-1/HS complex. This disruption inhibits the normal conduction of the mesenchymal-epithelial transition factor (cMET) signaling pathway, ultimately leading to EC ferroptosis and aggravation of the severity of ALI.¹⁴³

Circular RNAs can also participate in the regulation of ferroptosis of ECs in sepsis. For example, CircEXOC5 is highly expressed in patients with sepsis and cecal ligation and puncture (CLP) mice. Its upregulation promotes ferroptosis of primary mouse pulmonary microvascular endothelial cells (MPMECs) by recruiting IGF2BP2 to degrade *activating transcription factor 3 (Atf3)* mRNA, exacerbating sepsis-induced ALI.¹⁴⁴

Inhibition of ferroptosis can also improve the barrier function of ECs. Overexpression of growth differentiation factor 11 (GDF11) can inhibit ferroptosis and reduce sepsis-induced pulmonary microvascular endothelial barrier injury by activating the sirtuin 1 (SIRT1)/NADPH oxidase 4 (NOX4) signaling pathway, providing a new molecular target for the clinical treatment of ALI.¹⁴⁵ Thus, the alleviation of EC ferroptosis represents a promising protective strategy against sepsis.

Autophagy of ECs in Sepsis

Autophagy is a form of RCD that mechanistically depends on the autophagic machinery and its components, according to the NCCD.⁹³ As a highly conserved catabolic process, autophagy can eliminate cellular metabolic waste and maintain overall balance and homeostasis. In addition, the autophagy pathway can actively remove intracellular microorganisms and prevent microbial invasion by regulating inflammation and immunity, especially during sepsis.¹⁴⁶ Thus, autophagy, which serves as an important self-protection mechanism for cell survival, may be a promising therapeutic target for reversing sepsis-induced immunosuppression.¹⁴⁷ Recent studies related to sepsis have increasingly focused on the autophagy of ECs. Notably, these studies have demonstrated that the role of autophagy in sepsis may be contradictory.^{148,149} Therefore, this section mainly summarizes the autophagy and functional effects of ECs in the sepsis environment based on recent high-quality studies to further explain the complex mechanism of autophagy in sepsis (Figure 6).




Figure 6 The relationship of EC autophagy and function and EC autophagy-related mechanisms in sepsis. The impact of EC autophagy on its function is controversial. Late endosomal-dependent mitophagy induced by the SIRT1-Rab7 axis can attenuate NLRP3 and STING activation, thereby improving EC dysfunction, including inflammation and barrier function. *APOL1* risk variants can inhibit mitophagy, leading to the leakage of mtDNA into the cytoplasm, activation of NLRP3 and STING, and ultimately resulting in EC dysfunction. However, EC autophagy activated by thrombin or beclin 1 increases the degradation of VE-cadherin, which is important in maintaining EC barrier function. Moreover, EC autophagy-related mechanisms are mainly involved in the mTOR signaling pathway. Non-coding RNAs, such as circEXOC5, miR-210-3p, and miR-300, can also regulate EC autophagy. Created in BioRender. Jiang, L. (2024) <http://BioRender.com/r00x283>.

Autophagy deficiency will increase the susceptibility of the body to microbial infection, while enhanced autophagy may play an important role in improving inflammation and EC function. LC3B is a key autophagy protein involved in the formation and maturation of autophagosomes. Compared to wild-type normal mice, *Lc3b*-deficient mice exhibit higher mortality and more severe tissue and organ damage after CLP modeling. Moreover, these mice also exhibited increased bacterial counts in various organs, indicating that autophagy deficiency can lead to impaired bacterial clearance and resistance to polymicrobial sepsis.¹⁴⁸ In the study of sepsis-associated encephalopathy, promoting mitochondrial autophagy of cerebral microvascular ECs can block the activation of NLRP3 inflammasome, inhibit the secretion of IL-1 β to the central nervous system, reduce neuroinflammation, and improve cognitive dysfunction.¹⁵⁰ In sepsis-induced ALI, mitochondrial dysfunction is considered an important pathogenesis. One study identified a late endosome-dependent mitochondrial autophagy. SIRT1, a histone deacetylase, can interact with Rab7 on late endosomes to promote mitochondrial autophagy and limit the excessive activation of STING and NLRP3 in lung ECs, thereby playing a protective role.¹⁵¹ Moreover, treatment with the drug hyperoside can reduce LPS-induced damage to human lung microvascular ECs (HLMVECs) by activating autophagy-related (Atg) 13-mediated autophagy.¹⁵² In AKI caused by sepsis, the autophagy activator rapamycin can further enhance sepsis-induced autophagy in renal ECs and reduce renal endothelial injury and AKI. This finding supports the hypothesis that upregulation of autophagy in renal ECs may provide therapeutic benefits in sepsis-induced AKI.¹⁵³ Notably, the occurrence and severity of sepsis are closely associated with race. For example, the incidence and severity of sepsis in individuals of African ancestry are higher than those of European ancestry, and only individuals of African ancestry have genetic risk variants (RVs) in the *trypanolytic factor*

apolipoprotein L1 (APOLI). Moreover, RV *APOLI* can mediate mitochondrial autophagy defects in ECs, leading to the leakage of mitochondrial DNA (mtDNA) into the cytoplasm and activation of the NLRP3 and STING, resulting in an inflammatory and pro-adhesive endothelial phenotype that adversely affects sepsis.¹⁵⁴

In addition, numerous studies support that autophagy activation can aggravate sepsis and EC dysfunction. Autophagy activation can participate in impairing the endothelial barrier. In a study using the human microvascular endothelial cell line-1 and HUVEC, thrombin-induced macrophage migration inhibitory factor (MIF) secretion was found to promote autophagy by binding to CD74. This interaction leads to the disorganization and degradation of EC VE-cadherin, resulting in high permeability.¹⁵⁵ In contrast, the autophagy inhibitor hydroxychloroquine can significantly reduce LPS-induced endothelial hyperpermeability.¹⁵⁶ Beclin1, a key regulator of autophagy, has recently been found to serve as a new mechanistic link between autophagy and EC dysfunction, including inflammation and permeability. Silencing of *Beclin1* can downregulate the expression of pro-inflammatory genes, such as *NF-κB*, in ECs in response to thrombin, while also preventing the loss of VE-cadherin, thereby protecting the EC barrier function.¹⁵⁷

Based on current research, there is considerable controversy regarding the role of autophagy in sepsis. A comprehensive consideration of the occurrence and development process suggests that, in the early stage of infection, autophagy may be beneficial as it assists in clearance, resistance, and cell survival.¹⁵⁸ However, in the later stage of infection, continuous activation of autophagy may lead to uncontrolled vascular leakage and excessive inflammation.¹⁵⁹ From this perspective, the timing of autophagy regulation is crucial for the effective treatment of sepsis.

Finally, the review summarizes the important autophagy-related signaling pathways. mTOR is an important signaling pathway involved in the autophagy process. DI-3-n-butylphthalide, a drug that can improve multi-organ ischemic diseases, can alleviate the autophagy of microvascular ECs in CLP rats and improve their intestinal microcirculation disorders. This effect is achieved through the activation of the PI3K/Akt signaling pathway, which usually serves as the upstream regulator of mTOR.¹⁶⁰ Extracellular histones can induce autophagy in HUVECs by upregulating Sestrin2 and inhibiting the AKT/mTOR signaling pathway.¹⁰² There is also evidence indicating that in a sepsis mouse model, the overexpression of miR-300 can enhance autophagy by targeting nicotinamide phosphoribosyltransferase (NAMPT) and activating the AMP-activated protein kinase (AMPK)/mTOR signaling pathway, thereby inhibiting apoptosis and mitigating inflammatory responses.¹⁶¹ Non-coding RNAs can also participate in the regulation of autophagy. For example, circEXOC5 is implicated in the ferroptosis process of ECs during sepsis-induced ALI.¹³⁴ In addition, the upregulation of circEXOC5 is associated with increased inflammation and activated autophagy in ECs. This upregulation can promote inflammation and autophagy in MPMECs through the polypyrimidine tract binding protein 1 (PTBP1)/S-Phase kinase associated protein 2 (Skp2)/RUNX family transcription factor 2 (Runx2) signaling cascade and aggravate sepsis-induced ALI.¹⁴⁹ Conversely, miR-210-3p can decrease the expression of ATG7 and LC3II/LC3I and increase the expression of P62 in HLMVECs, thereby inhibiting autophagy.¹⁶²

Understanding the pathogenesis of sepsis, particularly RCD, poses a significant challenge in critical care medicine. RCD is a dynamic response of the body to internal and external environmental changes. The specific type of cell death depends on the microenvironment and the molecular mechanisms activated in response to stress. In addition to the RCD forms discussed above—including apoptosis, pyroptosis, ferroptosis, and autophagy—other forms of RCD, such as necroptosis, also participate in the development of sepsis.^{163,164} However, owing to the limitations in existing literature, we did not conduct a further review of these RCD forms. Different forms of cell death involve distinct pathways; however, they are also interconnected,⁹³ co-occurring and synergistically contributing to sepsis progression.^{102,165,166} Thus, recognizing that the different forms of RCD can counterbalance each other is essential. For instance, in an in vitro sepsis model using LPS-stimulated human umbilical vein ECs, an intervention with rapamycin to enhance autophagy was found to reduce the expressions of pyroptosis-related proteins, such as GSDMD and caspase-1, and decrease the secretions of IL-1β and IL-18, thereby improving the inflammatory microenvironment of sepsis and providing a potential therapeutic approach for sepsis treatment.¹⁶⁷ Furthermore, it must be acknowledged that RCD is a double-edged sword. Moderate cell death can remove damaged cells and facilitate tissue renewal, thus exerting a protective effect on the body. However, excessive apoptosis, pyroptosis, ferroptosis, or autophagy can significantly impair EC function, thereby compromising cell barrier integrity and vitality and contributing to the development of various diseases.

At present, the accumulated evidence enhances our understanding of the role of RCD in EC biology and sepsis-induced dysfunction. However, this evidence is predominately based on *in vitro* cell culture studies, primarily involving various ECs stimulated by LPS. *In vivo* studies have mainly focused on CLP or LPS-stimulated sepsis models, which still vary from real clinical scenarios of sepsis. Therefore, the current treatment strategies targeting RCD of ECs during sepsis remain largely hypothetical. Although the regulation of RCD by many commonly used RCD regulators, such as ferrostatin-1, rapamycin, and chloroquine, has been elucidated, their broad-spectrum effects *in vivo* limit their clinical applicability. Nevertheless, emerging drugs and interventions for regulating RCD in sepsis are also being developed and tested. For example, QiShenYiQi pills have been proven to improve pulmonary diseases clinically; however, their role in sepsis remains unknown. One study suggested that QiShen YiQi pills may inhibit ferroptosis in ECs by inhibiting the RAGE pathway and the target cyclooxygenase-2, thereby maintaining the integrity of the pulmonary vascular barrier in CLP mice. Therefore, these pills could be a promising option for treating sepsis-induced ALI.¹⁶⁸ Another study has indicated that hepatocyte growth factor (HGF) can partially improve pyroptosis in ECs and alleviate vascular endothelial injury in septic animals by activating the mTOR signaling pathway, thereby protecting mitochondrial physiological functions and alleviating ALI.¹⁶⁹ Finally, new treatment methods should be further verified in various preclinical models. Future research and discoveries of sepsis-related pathways will aid in identifying other therapeutic targets.

Conclusion

EC dysfunction plays a critical role in sepsis development and leads to organ dysfunction. The primary manifestations of endothelial damage include barrier dysfunction and various forms of RCD. Barrier dysfunction can promote white blood cell migration and enhance inflammatory responses. A heightened inflammatory response can increase the risk of EC death through complex mechanisms, thereby hindering the repair of sepsis-induced damage. Through a systematic literature review, we identified multiple factors contributing to barrier dysfunction in ECs, including GCX degradation and shedding and the release of various DAMPs. RCD in ECs, such as apoptosis, pyroptosis, ferroptosis, and autophagy, is closely linked to the high levels of inflammation and oxidative stress induced by sepsis. Thus, investigating the interconnections and regulatory relationships between various modes of cell death is crucial. With the recent advancements in single-cell sequencing and multi-omics technologies, further exploration of the pathological molecular mechanisms underlying endothelial dysfunction in sepsis, as well as identifying effective treatment targets and developing specific small-molecule drugs, remain a focal point for future research.

Abbreviations

ADAM15, a disintegrin and metalloproteinase 15; ADSC, adipose-derived stem cell; AKI, acute kidney injury; AKT, protein kinase B; ALI: acute lung injury; AMPK, AMP-activated protein kinase; Ang1, angiopoietin-1; APOL1, apolipoprotein L1; ARDS, acute respiratory distress syndrome; ATF3, activating transcription factor 3; ATG7, autophagy-related 7; ceRNA, competing endogenous RNA; cGAS, cyclic GMP-AMP synthase; CLP, cecal ligation and puncture; cMET, the mesenchymal-epithelial transition factor; DAMPs, damage-associated molecular patterns; DIC, disseminated intravascular coagulation; eCIRP, extracellular cold-inducible RNA-binding protein; ECs, endothelial cells; ER, endoplasmic reticulum; GAB1, GRB2 associated binding protein 1; GCX, glycocalyx; GDF11, growth differentiation factor 11; GPX4, glutathione peroxidase 4; GSDMD, gasdermin D; GSDMD-NT, gasdermin D N-terminal fragment; HA, hyaluronic acid; HIF-1 α , hypoxia-inducible factor-1 α ; HLMVEC, human lung microvascular ECs; HMGB1, high mobility group box 1; HNP, human neutrophil peptides; HO-1, heme oxygenase-1; HPCAECs, human primary coronary artery ECs; HPMECs, human pulmonary microvascular endothelial cells; HPSE, heparanase; HS, heparan sulfate; HUVECs, human umbilical vein endothelial cells; ICAM1, intercellular adhesion molecule 1; IFN, interferon; IL-1 β , interleukin-1 β ; ILC2, group 2 innate lymphoid cells; iNOS, inducible nitric oxide synthase; IRE1 α , inositol requiring enzyme-1 α ; KEAP1, kelch-like ECH-associated protein-1; lncRNAs, long non-coding RNAs; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MD2, myeloid differentiation protein-2; MIF, macrophage migration inhibitory factor; miRNAs, microRNAs; MPMECs, mouse pulmonary microvascular endothelial cells; mtDNA, mitochondrial DNA; mTOR, mammalian target of rapamycin; NAMPT, nicotinamide phosphoribosyltransferase; NCCD, Nomenclature Committee on Cell Death; NET, neutrophil extracellular traps; NF- κ B, nuclear factor kappa-B; NLRP3, nucleotide-

binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3; NLRX1, NLR family member X1; NO, nitric oxide; NOX4, NADPH oxidase 4; NRF2, nuclear factor erythroid 2-related factor 2; NRP2, neuropilin 2; O-GlcNAc, O-linked β -N-acetylglucosamine; Ox-HMGB1, oxidized HMGB1; P2X7, P2X ligand-gated ion channel 7; PAMPs, pathogen-associated molecular patterns; PECAM-1, platelet endothelial cell adhesion molecule-1; PI3K, phosphoinositide-3-kinase; PTBP1, polypyrimidine tract binding protein 1; PTMs, post-translational modifications; RAGE, receptor for advanced glycation end-products; RCD, regulated cell death; ROCK1, Rho-associated coiled-coil containing protein kinase 1; ROS, reactive oxygen species; Runx2, RUNX family transcription factor 2; SDC-1, syndecan-1; SERP1, stress-associated endoplasmic reticulum protein 1; SIRT1, sirtuin 1; Skp2, S-Phase kinase associated protein 2; SLIT2, slit guidance ligand 2; SSH1, slingshot protein phosphatase 1; ST2, suppression of tumorigenicity 2; STAT, signal transducer and activator of transcription; STEAP1, six transmembrane epithelial antigen of the prostate 1; STING, stimulator of interferon genes; TJ, tight junction; TLR4, toll-like receptor 4; TNF- α , tumor necrosis factor-alpha; TUG1, taurine-upregulated gene 1; TXNIP, thioredoxin-interacting protein; VCAM1, vascular cell adhesion molecule 1; VE-cadherin, vascular endothelial cadherin; YAP, yes-associated protein; ZO-1, zona occludens-1.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81930057, 81772076), Shanghai Rising Star Program (22QA1411700); Youth Medical Talents-Specialist Program, CAMS Innovation Fund for Medical Sciences (2019-I2M-5-076), and Achievements Supportive Fund (2018-CGPZ-B03). The graphical abstract was Created in BioRender. Jiang, L. (2024) <http://BioRender.com/b42n502>.

Author Contributions

All authors made a significant contribution to the work reported, including the conception, study design, execution, acquisition of data, analysis, and interpretation. They all participated in drafting, revising, or critically reviewing the article; provided final approval of the version to be published; and agreed to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA*. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
2. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study. *Lancet*. 2020;395(10219):200–211. doi:10.1016/S0140-6736(19)32989-7
3. Joffre J, Hellman J, Ince C, Ait-Oufella H. Endothelial responses in sepsis. *Am J Respir Crit Care Med*. 2020;202(3):361–370. doi:10.1164/rccm.201910-1911TR
4. Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. *Lancet*. 2022;400(10358):1145–1156. doi:10.1016/S0140-6736(22)01485-4
5. Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. *Burns Trauma*. 2014;2(3):97–105. doi:10.4103/2321-3868.132689
6. Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. *Kidney Int*. 2019;96(5):1083–1099. doi:10.1016/j.kint.2019.05.026
7. Gao Q, Hernandez MS. Sepsis-associated encephalopathy and blood-brain barrier dysfunction. *Inflammation*. 2021;44(6):2143–2150. doi:10.1007/s10753-021-01501-3
8. Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. *Semin Thromb Hemost*. 2020;46(1):89–95. doi:10.1055/s-0039-1694995
9. Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red. *Fed Proc*. 1966;25(6):1773–1783.
10. Suzuki A, Tomita H, Okada H. Form follows function: the endothelial glycocalyx. *Transl Res*. 2022;247:158–167. doi:10.1016/j.trsl.2022.03.014
11. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. *Ann Rev Bio Eng*. 2007;9(1):121–167. doi:10.1146/annurev.bioeng.9.060906.151959
12. Mahmoud M, Mayer M, Cancel LM, Bartosch AM, Mathews R, Tarbell JM. The glycocalyx core protein Glypican 1 protects vessel wall endothelial cells from stiffness-mediated dysfunction and disease. *Cardiovasc Res*. 2021;117(6):1592–1605. doi:10.1093/cvr/cvaa201
13. Heimerl M, Gausepohl T, Mueller JH, Ricke-Hoch M. Neuraminidases-key players in the inflammatory response after pathophysiological cardiac stress and potential new therapeutic targets in cardiac disease. *Biology*. 2022;11(8):1229. doi:10.3390/biology11081229

14. Urschel K, Tauchi M, Achenbach S, Dietel B. Investigation of wall shear stress in cardiovascular research and in clinical practice—from bench to bedside. *Int J Mol Sci.* 2021;22(11):5635. doi:10.3390/ijms22115635
15. Malik AB, Lynch JJ, Cooper JA. Endothelial barrier function. *J Invest Dermatol.* 1989;93(2 Suppl):62S–67S. doi:10.1111/1523-1747.ep12581072
16. Schmidt EP, Yang Y, Janssen WJ, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. *Nat Med.* 2012;18(8):1217–1223. doi:10.1038/nm.2843
17. Toledo AG, Golden G, Campos AR, et al. Proteomic atlas of organ vasculopathies triggered by *Staphylococcus aureus* sepsis. *Nat Commun.* 2019;10(1):4656. doi:10.1038/s41467-019-12672-x
18. Dogné S, Flamion B. Endothelial glycocalyx impairment in disease: focus on hyaluronan shedding. *Am J Pathol.* 2020;190(4):768–780. doi:10.1016/j.ajpath.2019.11.016
19. Yang X, Meegan JE, Jannaway M, Coleman DC, Yuan SY. A disintegrin and metalloproteinase 15-mediated glycocalyx shedding contributes to vascular leakage during inflammation. *Cardiovasc Res.* 2018;114(13):1752–1763. doi:10.1093/cvr/cvy167
20. Hippensteel JA, Uchimido R, Tyler PD, et al. Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation. *Crit Care.* 2019;23(1):259. doi:10.1186/s13054-019-2534-2
21. Rahbar E, Cardenas JC, Baimukanova G, et al. Endothelial glycocalyx shedding and vascular permeability in severely injured trauma patients. *J Transl Med.* 2015;13:117. doi:10.1186/s12967-015-0481-5
22. Delgadillo LF, Lomakina EB, Kuebel J, Waugh RE. Changes in endothelial glycocalyx layer protective ability after inflammatory stimulus. *Am J Physiol Cell Physiol.* 2021;320(2):C216–C224. doi:10.1152/ajpcell.00259.2020
23. Puskarich M, Cornelius D, Tharp J, Nandi U, Jones A. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. *J Crit Care.* 2016;36. doi:10.1016/j.jcrc.2016.06.027
24. Saoraya J, Wongsamita L, Srisawat N, Musikatavorn K. Plasma syndecan-1 is associated with fluid requirements and clinical outcomes in emergency department patients with sepsis. *Am J Emerg Med.* 2021;42:83–89. doi:10.1016/j.ajem.2021.01.019
25. Goligorsky MS, Sun D. Glycocalyx in endotoxemia and sepsis. *Am J Pathol.* 2020;190(4):791–798. doi:10.1016/j.ajpath.2019.06.017
26. McGarrity S, Anuforo O, Halldórsson H, et al. Metabolic systems analysis of LPS induced endothelial dysfunction applied to sepsis patient stratification. *Sci Rep.* 2018;8:6811. doi:10.1038/s41598-018-25015-5
27. Eustes AS, Campbell RA, Middleton EA, et al. Heparanase expression and activity are increased in platelets during clinical sepsis. *J Thromb Haemost.* 2021;19(5):1319–1330. doi:10.1111/jth.15266
28. Vlodaysky I, Barash U, Nguyen HM, Yang SM, Ilan N. Biology of the heparanase–heparan sulfate axis and its role in disease pathogenesis. *Semin Thromb Hemost.* 2021;47(3):240–253. doi:10.1055/s-0041-1725066
29. Tang Y, Wang X, Li Z, et al. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. *Immunity.* 2021;54(3):454–467.e6. doi:10.1016/j.immuni.2021.01.007
30. Cassinelli G, Torri G, Naggi A. Non-anticoagulant heparins as heparanase inhibitors. *Adv Exp Med Biol.* 2020;1221:493–522. doi:10.1007/978-3-030-34521-1_20
31. Villalba N, Baby S, Yuan SY. The endothelial glycocalyx as a double-edged sword in microvascular homeostasis and pathogenesis. *Front Cell Dev Biol.* 2021;9:711003. doi:10.3389/fcell.2021.711003
32. Daiber A, Chlopicki S. Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: evidence for redox-based therapies. *Free Radic Biol Med.* 2020;157:15–37. doi:10.1016/j.freeradbiomed.2020.02.026
33. Potje SR, Grando MD, Chignalia AZ, Antoniali C, Bendhack LM. Reduced caveolae density in arteries of SHR contributes to endothelial dysfunction and ROS production. *Sci Rep.* 2019;9(1):6696. doi:10.1038/s41598-019-43193-8
34. Potje SR, Paula TDC, Paulo M, Bendhack LM. The role of glycocalyx and caveolae in vascular homeostasis and diseases. *Front Physiol.* 2021;11:620840. doi:10.3389/fphys.2020.620840
35. Montorfano I, Becerra A, Cerro R, et al. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF- β 1 and TGF- β 2-dependent pathway. *Lab Invest.* 2014;94(10):1068–1082. doi:10.1038/labinvest.2014.100
36. Li J, Qi Z, Li D, et al. Alveolar epithelial glycocalyx shedding aggravates the epithelial barrier and disrupts epithelial tight junctions in acute respiratory distress syndrome. *Biomed Pharmacother.* 2021;133:111026. doi:10.1016/j.biopha.2020.111026
37. Huang X, Han S, Liu X, et al. Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis. *Exp Ther Med.* 2020;19(2):913–922. doi:10.3892/etm.2019.8285
38. Golden GJ, Toledo AG, Marki A, et al. Endothelial heparan sulfate mediates hepatic neutrophil trafficking and injury during *Staphylococcus aureus* sepsis. *mBio.* 2021;12(5):e01181–21. doi:10.1128/mBio.01181-21
39. Wang L, Fuster M, Sriramarao P, Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. *Nat Immunol.* 2005;6(9):902–910. doi:10.1038/ni1233
40. Fuster MM, Wang L, Castagnola J, et al. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. *J Cell Biol.* 2007;177(3):539–549. doi:10.1083/jcb.200610086
41. Campeau MA, Leask RL. Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption. *Sci Rep.* 2022;12:12681. doi:10.1038/s41598-022-16763-6
42. Campeau MA, Leask RL. Empagliflozin reduces endoplasmic reticulum stress associated TXNIP/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2023. doi:10.1007/s00210-023-02607-1
43. Denning NL, Aziz M, Gurien SD, Wang P. DAMPs and NETs in sepsis. *Front Immunol.* 2019;10:2536. doi:10.3389/fimmu.2019.02536
44. Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. *Exp Mol Med.* 2022;54(2):91–102. doi:10.1038/s12276-022-00736-w
45. Erdei J, Tóth A, Balogh E, et al. Induction of NLRP3 inflammasome activation by heme in human endothelial cells. *Oxid Med Cell Longev.* 2018;2018:4310816. doi:10.1155/2018/4310816
46. Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. *Annu Rev Immunol.* 2010;28:321–342. doi:10.1146/annurev-immunol-030409-101311
47. Ramasubramanian B, Kim J, Ke Y, et al. Mechanisms of pulmonary endothelial permeability and inflammation caused by extracellular histone subunits h3 and h4 . *FASEB J.* 2022;36(9):e22470. doi:10.1096/fj.202200303RR

48. Ferrari S, Ronfani L, Calogero S, Bianchi ME. The mouse gene coding for high mobility group 1 protein (HMGB1). *J Biol Chem.* 1994;269(46):28803–28808.
49. Deng C, Zhao L, Yang Z, et al. Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury. *Acta Pharmacol Sin.* 2022;43(3):520–528. doi:10.1038/s41401-021-00676-7
50. Yang X, Cheng X, Tang Y, et al. The role of type 1 interferons in coagulation induced by gram-negative bacteria. *Blood.* 2020;135(14):1087–1100. doi:10.1182/blood.2019002282
51. Yang K, Fan M, Wang X, et al. Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis. *Cell Death Differ.* 2022;29(1):133–146. doi:10.1038/s41418-021-00841-9
52. Deng M, Tang Y, Li W, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. *Immunity.* 2018;49(4):740–753.e7. doi:10.1016/j.immuni.2018.08.016
53. Zhang S, Feng F, Dai J, Li J, Bu X, Xie X. Recombinant high-mobility group box 1 (rHMGB1) promotes NRF2-independent mitochondrial fusion through CXCR4/PSMB5-mediated Drp1 degradation in endothelial cells. *Oxid Med Cell Longev.* 2021;2021:9993240. doi:10.1155/2021/9993240
54. Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. *Signal Transduct Target Ther.* 2024;9(1):124. doi:10.1038/s41392-024-01839-8
55. Yao CH, Wang R, Wang Y, Kung CP, Weber JD, Patti GJ. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. *eLife.* 2019;8:e41351. doi:10.7554/eLife.41351
56. Lan J, Luo H, Wu R, et al. Internalization of HMGB1 (High mobility group box 1) promotes angiogenesis in endothelial cells. *ATVB.* 2020;40(12):2922–2940. doi:10.1161/ATVBAHA.120.315151
57. Sekine S, Ehara H, Kujirai T, Kurumizaka H. Structural perspectives on transcription in chromatin. *Trends Cell Biol.* 2024;34(3):211–224. doi:10.1016/j.tcb.2023.07.011
58. Russell RT, Christiaans SC, Nice TR, et al. Histone-complexed DNA fragments levels are associated with coagulopathy, endothelial cell damage, and increased mortality after severe pediatric trauma. *Shock.* 2018;49(1):44–52. doi:10.1097/SHK.0000000000000902
59. Szatmary P, Huang W, Criddle D, Tepikin A, Sutton R. Biology, role and therapeutic potential of circulating histones in acute inflammatory disorders. *J Cell Mol Med.* 2018;22(10):4617–4629. doi:10.1111/jcmm.13797
60. Yang T, Li Y, Su B. Understanding the multiple roles of extracellular histones in mediating endothelial dysfunction. *J Am Soc Nephrol.* 2022;33(10):1951. doi:10.1681/ASN.2022060640
61. Li Y, Wan D, Luo X, et al. Circulating histones in sepsis: potential outcome predictors and therapeutic targets. *Front Immunol.* 2021;12:650184. doi:10.3389/fimmu.2021.650184
62. Cheng Z, Abrams ST, Alhamdi Y, et al. Circulating histones are major mediators of multiple organ dysfunction syndrome in acute critical illnesses. *Crit Care Med.* 2019;47(8):e677–e684. doi:10.1097/CCM.0000000000003839
63. Garcia-Giménez JL, Garcia-López E, Mena-Mollá S, et al. Validation of circulating histone detection by mass spectrometry for early diagnosis, prognosis, and management of critically ill septic patients. *J Transl Med.* 2023;21(1):344. doi:10.1186/s12967-023-04197-1
64. Tsurouktsoglou TD, Warnatsch A, Ioannou M, Hoving D, Wang Q, Papayannopoulos V. Histones, DNA, and citrullination promote neutrophil extracellular trap inflammation by regulating the localization and activation of TLR4. *Cell Rep.* 2020;31(5). doi:10.1016/j.celrep.2020.107602
65. Kim J, Baalachandran R, Li Y, et al. Circulating extracellular histones exacerbate acute lung injury by augmenting pulmonary endothelial dysfunction via TLR4-dependent mechanism. *Am J Physiol Lung Cell Mol Physiol.* 2022;323(3):L223–L239. doi:10.1152/ajplung.00072.2022
66. Immenschuh S, Vijayan V, Janciauskiene S, Gueler F. Heme as a Target for Therapeutic Interventions. *Front Pharmacol.* 2017;8:146. doi:10.3389/fphar.2017.00146
67. Tsiftoglou AS, Tsamadou AI, Papadopoulou LC. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. *Pharmacol Ther.* 2006;111(2):327–345. doi:10.1016/j.pharmthera.2005.10.017
68. Ryter SW. Significance of heme and heme degradation in the pathogenesis of acute lung and inflammatory disorders. *Int J Mol Sci.* 2021;22(11):5509. doi:10.3390/ijms22115509
69. Larsen R, Gozzelino R, Jeney V, et al. A central role for free heme in the pathogenesis of severe sepsis. *Sci Trans Med.* 2010;2(51):51ra71–51ra71. doi:10.1126/scitranslmed.3001118
70. Dutra FF, Alves LS, Rodrigues D, et al. Hemolysis-induced lethality involves inflammasome activation by heme. *Proc Natl Acad Sci U S A.* 2014;111(39):E4110–E4118. doi:10.1073/pnas.1405023111
71. Nyakundi BB, Tóth A, Balogh E, et al. Oxidized hemoglobin forms contribute to NLRP3 inflammasome-driven IL-1 β production upon intravascular hemolysis. *Biochim Biophys Acta Mol Basis Dis.* 2019;1865(2):464–475. doi:10.1016/j.bbdis.2018.10.030
72. Calay D, Mason JC. The multifunctional role and therapeutic potential of HO-1 in the vascular endothelium. *Antioxid Redox Signal.* 2014;20(11):1789–1809. doi:10.1089/ars.2013.5659
73. Luo W, Wang Y, Yang H, et al. Heme oxygenase-1 ameliorates oxidative stress-induced endothelial senescence via regulating endothelial nitric oxide synthase activation and coupling. *Aging.* 2018;10(7):1722–1744. doi:10.18632/aging.101506
74. Cen M, Ouyang W, Zhang W, et al. MitoQ protects against hyperpermeability of endothelium barrier in acute lung injury via a Nrf2-dependent mechanism. *Redox Biol.* 2021;41:101936. doi:10.1016/j.redox.2021.101936
75. James J, Srivastava A, Varghese MV, et al. Heme induces rapid endothelial barrier dysfunction via the MKK3/p38MAPK axis. *Blood.* 2020;136(6):749–754. doi:10.1182/blood.2019003986
76. Yang H, Wang H, Andersson U. Targeting inflammation driven by HMGB1. *Front Immunol.* 2020;11. doi:10.3389/fimmu.2020.00484
77. Banerjee S, Rakshit T, Sett S, Mukhopadhyay R. Interactions of histone acetyltransferase p300 with the nuclear proteins histone and HMGB1, as revealed by single molecule atomic force spectroscopy. *J Phys Chem B.* 2015;119(42):13278–13287. doi:10.1021/acs.jpcc.5b07795
78. Tang Y, Zhao X, Antoine D, et al. Regulation of posttranslational modifications of HMGB1 during immune responses. *Antioxid Redox Signal.* 2016;24(12):620–634. doi:10.1089/ars.2015.6409
79. Ren W, Zhao L, Sun Y, Wang X, Shi X. HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases. *Mol Med.* 2023;29(1):117. doi:10.1186/s10020-023-00717-3
80. Liu J, Pang SY, Zhou SY, et al. Lipocalin-2 aggravates blood-brain barrier dysfunction after intravenous thrombolysis by promoting endothelial cell ferroptosis via regulating the HMGB1/Nrf2/HO-1 pathway. *Redox Biol.* 2024;76:103342. doi:10.1016/j.redox.2024.103342

81. Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. *Biochim Biophys Acta*. 2016;1863(12):2977–2992. doi:10.1016/j.bbamcr.2016.09.012
82. Joffre J, Hellman J. Oxidative stress and endothelial dysfunction in sepsis and acute inflammation. *Antioxid Redox Signal*. 2021;35(15):1291–1307. doi:10.1089/ars.2021.0027
83. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. *Tren Immunol*. 2007;28(10):429–436. doi:10.1016/j.it.2007.08.004
84. Wang S, Zhang K, Huang Q, Meng F, Deng S. TLR4 signalling in ischemia/reperfusion injury: a promising target for linking inflammation, oxidative stress and programmed cell death to improve organ transplantation outcomes. *Front Immunol*. 2024;15:1447060. doi:10.3389/fimmu.2024.1447060
85. Kwak MS, Rhee WJ, Lee YJ, et al. Reactive oxygen species induce Cys106-mediated anti-parallel HMGB1 dimerization that protects against DNA damage. *Redox Biol*. 2021;40:101858. doi:10.1016/j.redox.2021.101858
86. Terry AQ, Kojima H, Sosa RA, et al. Disulfide-HMGB1 signals through TLR4 and TLR9 to induce inflammatory macrophages capable of innate-adaptive crosstalk in human liver transplantation. *Am J Transplant*. 2023;23(12):1858–1871. doi:10.1016/j.ajt.2023.08.002
87. Gáll T, Balla G, Balla J. Heme, heme oxygenase, and endoplasmic reticulum stress—a new insight into the pathophysiology of vascular diseases. *Int J Mol Sci*. 2019;20(15):3675. doi:10.3390/ijms20153675
88. Guo Y, Zhao H, Lin Z, Ye T, Xu D, Zeng Q. Heme in cardiovascular diseases: a ubiquitous dangerous molecule worthy of vigilance. *Front Cell Dev Biol*. 2021;9:781839. doi:10.3389/fcell.2021.781839
89. Bozza MT, Jeney V. Pro-inflammatory actions of heme and other hemoglobin-derived DAMPs. *Front Immunol*. 2020;11:1323. doi:10.3389/fimmu.2020.01323
90. Pethő D, Hendrik Z, Nagy A, et al. Heme cytotoxicity is the consequence of endoplasmic reticulum stress in atherosclerotic plaque progression. *Sci Rep*. 2021;11(1):10435. doi:10.1038/s41598-021-89713-3
91. Galluzzi L, Bravo-San Pedro JM, Kepp O, Kroemer G. Regulated cell death and adaptive stress responses. *Cell Mol Life Sci*. 2016;315(11–12):2405–2410. doi:10.1007/s00018-016-2209-y
92. Galluzzi L, Bravo-San Pedro JM, Vitale I, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death Differ*. 2015;22(1):58–73. doi:10.1038/cdd.2014.137
93. Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. *Cell Death Differ*. 2018;25(3):486–541. doi:10.1038/s41418-017-0012-4
94. Fu H, Wang Q, Luo Q, et al. Simvastatin inhibits apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. *World J Emerg Med*. 2014;5(4):291. doi:10.5847/wjem.j.issn.1920-8642.2014.04.009
95. Dong Y, Fan G, Li Y, Zhou Q. TUG1 represses apoptosis, autophagy, and inflammatory response by regulating miR-27a-3p/SLIT2 in lipopolysaccharide-treated vascular endothelial cells. *J Surg Res*. 2020;256:345–354. doi:10.1016/j.jss.2020.05.102
96. Hou Y, Wang XF, Lang ZQ, et al. Adiponectin is protective against endoplasmic reticulum stress-induced apoptosis of endothelial cells in sepsis. *Braz J Med Biol Res*. 2018;51(12):e7747. doi:10.1590/1414-431X20187747
97. Zhao S, Gao J, Li J, Wang S, Yuan C, Liu Q. PD-L1 regulates inflammation in LPS-induced lung epithelial cells and vascular endothelial cells by interacting with the HIF-1 α signaling pathway. *Inflammation*. 2021;44(5):1969–1981. doi:10.1007/s10753-021-01474-3
98. Li M, Liu Y, Fu Y, et al. Interleukin-35 inhibits lipopolysaccharide-induced endothelial cell activation by downregulating inflammation and apoptosis. *Exp Cell Res*. 2021;407(2):112784. doi:10.1016/j.yexcr.2021.112784
99. Cai M, Li S, Shuai Y, Li J, Tan J, Zeng Q. Genome-wide CRISPR-Cas9 viability screen reveals genes involved in TNF- α -induced apoptosis of human umbilical vein endothelial cells. *J Cell Physiol*. 2019;234(6):9184–9193. doi:10.1002/jcp.27595
100. Yi L, Huang X, Guo F, et al. Lipopolysaccharide induces human pulmonary micro-vascular endothelial apoptosis via the YAP signaling pathway. *Front Cell Infect Microbiol*. 2016;6. doi:10.3389/fcimb.2016.00133
101. Liu Z, Ji J, Zheng D, Su L, Peng T, Tang J. Protective role of endothelial calpain knockout in lipopolysaccharide-induced acute kidney injury via attenuation of the p38-iNOS pathway and NO/ROS production. *Exp Mol Med*. 2020;52(4):702–712. doi:10.1038/s12276-020-0426-9
102. Ibañez-Cabellos JS, Aguado C, Pérez-Cremades D, et al. Extracellular histones activate autophagy and apoptosis via mTOR signaling in human endothelial cells. *Biochim Biophys Acta Mol Basis Dis*. 2018;1864(10):3234–3246. doi:10.1016/j.bbdis.2018.07.010
103. Liu ZF, Zheng D, Fan GC, Peng T, Su L. Heat stress prevents lipopolysaccharide-induced apoptosis in pulmonary microvascular endothelial cells by blocking calpain/p38 MAPK signalling. *Apoptosis*. 2016;21(8):896–904. doi:10.1007/s10495-016-1263-0
104. Cai GL, Yang ZX, Guo DY, Hu CB, Yan ML, Yan J. Macrophages enhance lipopolysaccharide induced apoptosis via Ang1 and NF- κ B pathways in human umbilical vein endothelial cells. *Sci Rep*. 2021;11(1):2918. doi:10.1038/s41598-021-82531-7
105. Qiu N, Xu X, He Y. LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1. *BMC Pulm Med*. 2020;20(1):49. doi:10.1186/s12890-020-1084-3
106. Zhang Z, Lv M, Wang X, Zhao Z, Jiang D, Wang L. LncRNA LUADT1 sponges miR-195 to prevent cardiac endothelial cell apoptosis in sepsis. *Mol Med*. 2020;26(1):112. doi:10.1186/s10020-020-00228-5
107. Jiang WY, Ren J, Zhang XH, et al. CircC3P1 attenuated pro-inflammatory cytokine production and cell apoptosis in acute lung injury induced by sepsis through modulating miR-21. *J Cell Mol Med*. 2020;24(19):11221–11229. doi:10.1111/jcmm.15685
108. Mu Q, Zhang C, Li R, Guo Z. CircPalm2 knockdown alleviates LPS-evoked pulmonary microvascular endothelial cell apoptosis and inflammation via miR-450b-5p/ROCK1 axis. *Int Immunopharmacol*. 2022;113(Pt A):109199. doi:10.1016/j.intimp.2022.109199
109. Gao M, Yu T, Liu D, et al. Sepsis plasma-derived exosomal miR-1-3p induces endothelial cell dysfunction by targeting SERP1. *Clin Sci*. 2021;135(2):347–365. doi:10.1042/CS20200573
110. Yao Y, Jia H, Wang G, Ma Y, Sun W, Li P. miR-297 protects human umbilical vein endothelial cells against LPS-induced inflammatory response and apoptosis. *Cell Physiol Biochem*. 2019;52(4):696–707. doi:10.33594/000000049
111. Pan D, Zhu J, Cao L, Zhu B, Lin L. Ruscogenin attenuates lipopolysaccharide-induced septic vascular endothelial dysfunction by modulating the miR-146a-5p/NRP2/SSH1 axis. *Drug Des Devel Ther*. 2022;16:1099–1106. doi:10.2147/DDDT.S356451
112. Xu F, Yuan J, Tian S, Chen Y, Zhou F. MicroRNA-92a serves as a risk factor in sepsis-induced ARDS and regulates apoptosis and cell migration in lipopolysaccharide-induced HPMEC and A549 cell injury. *Life Sci*. 2020;256:117957. doi:10.1016/j.lfs.2020.117957

113. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. *Nature*. 2012;481(7381):278–286. doi:10.1038/nature10759
114. Wallach D, Kang TB, Dillon CP, Green DR. Programmed necrosis in inflammation: toward identification of the effector molecules. *Science*. 2016;352(6281):aaf2154. doi:10.1126/science.aaf2154
115. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature*. 2009;458(7242):1191–1195. doi:10.1038/nature07830
116. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. *Trends Biochem Sci*. 2017;42(4):245–254. doi:10.1016/j.tibs.2016.10.004
117. Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. 2015;526(7575):666–671. doi:10.1038/nature15541
118. Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. *Nature*. 2016;535(7610):153–158. doi:10.1038/nature18629
119. Huang LS, Hong Z, Wu W, et al. mtDNA activates cGAS signaling and suppresses the YAP-mediated endothelial cell proliferation program to promote inflammatory injury. *Immunity*. 2020;52(3):475–486.e5. doi:10.1016/j.immuni.2020.02.002
120. Liu H, Tang D, Zhou X, Yang X, Chen AF. Phospholipase C γ 1/calcium-dependent membranous localization of Gsdmd-N drives endothelial pyroptosis, contributing to lipopolysaccharide-induced fatal outcome. *Am J Physiol Heart Circ Physiol*. 2020;319(6):H1482–H1495. doi:10.1152/ajpheart.00731.2019
121. Yu F, Zhang Z, Leng Y, Chen AF. O-GlcNAc modification of GSDMD attenuates LPS-induced endothelial cells pyroptosis. *Inflamm Res*. 2024;73(1):5–17. doi:10.1007/s00011-023-01812-1
122. Beltrán-García J, Osca-Verdegal R, Pérez-Cremades D, et al. Extracellular histones activate endothelial NLRP3 inflammasome and are associated with a severe sepsis phenotype. *J Inflamm Res*. 2022;15:4217–4238. doi:10.2147/JIR.S363693
123. Aziz M, Brenner M, Wang P. Extracellular CIRP (eCIRP) and inflammation. *J Leukoc Biol*. 2019;106(1):133–146. doi:10.1002/JLB.3MIR1118-443R
124. Yang WL, Sharma A, Wang Z, Li Z, Fan J, Wang P. Cold-inducible RNA-binding protein causes endothelial dysfunction via activation of Nlrp3 inflammasome. *Sci Rep*. 2016;6:26571. doi:10.1038/srep26571
125. Su Y, Yin X, Huang X, Guo Q, Ma M, Guo L. The BCL2/BAX/ROS pathway is involved in the inhibitory effect of astragaloside IV on pyroptosis in human umbilical vein endothelial cells. *Pharm Biol*. 2022;60(1):1812–1818. doi:10.1080/13880209.2022.2101668
126. Chen Q, Hakimi M, Wu S, et al. Increased genomic copy number of DEFA1/DEFA3 is associated with susceptibility to severe sepsis in Chinese Han population. *Anesthesiology*. 2010;112(6):1428–1434. doi:10.1097/ALN.0b013e3181d968eb
127. Chen Q, Yang Y, Hou J, et al. Increased gene copy number of DEFA1/DEFA3 worsens sepsis by inducing endothelial pyroptosis. *Proc Natl Acad Sci USA*. 2019;116(8):3161–3170. doi:10.1073/pnas.1812947116
128. Napier BA, Brubaker SW, Sweeney TE, et al. Complement pathway amplifies caspase-11-dependent cell death and endotoxin-induced sepsis severity. *J Exp Med*. 2016;213(11):2365–2382. doi:10.1084/jem.20160027
129. Lendak D, Mihajlovic D, Mitic G, et al. Complement component consumption in sepsis correlates better with hemostatic system parameters than with inflammatory biomarkers. *Thromb Res*. 2018;170:126–132. doi:10.1016/j.thromres.2018.08.013
130. Feng Q, Zhang YS, Zhuang Y, et al. Inhibition of the C3a receptor attenuates sepsis-induced acute lung injury by suppressing pyroptosis of the pulmonary vascular endothelial cells. *Free Radic Biol Med*. 2022;184:208–217. doi:10.1016/j.freeradbiomed.2022.02.032
131. Lai D, Tang J, Chen L, et al. Group 2 innate lymphoid cells protect lung endothelial cells from pyroptosis in sepsis. *Cell Death Dis*. 2018;9(3):369. doi:10.1038/s41419-018-0412-5
132. Yang R, Zhang X. A potential new pathway for heparin treatment of sepsis-induced lung injury: inhibition of pulmonary endothelial cell pyroptosis by blocking hMGB1-LPS-induced caspase-11 activation. *Front Cell Infect Microbiol*. 2022;12:984835. doi:10.3389/fcimb.2022.984835
133. Zhan F, Zhang J, He P, Chen W, Ouyang Y. Macrophage-derived exosomal miRNA-141 triggers endothelial cell pyroptosis by targeting NLRP3 to accelerate sepsis progression. *Int J Immunopathol Pharmacol*. 2024;38:03946320241234736. doi:10.1177/03946320241234736
134. Hirschhorn T, Stockwell BR, et al. The development of the concept of ferroptosis. *Free Radic Biol Med*. 2019; 130:130–143. doi:10.1016/j.freeradbiomed.2018.09.043
135. Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. *Cell*. 2022; 184(14): 2401–2421. doi:10.1016/j.cell.2022.06.003
136. Li FJ, Hu H, Wu L, et al. Ablation of mitophagy receptor FUNDC1 accentuates septic cardiomyopathy through ACSL4-dependent regulation of ferroptosis and mitochondrial integrity. *Free Radic Biol Med*. 2024;S0891–5849(24):686. doi:10.1016/j.freeradbiomed.2024.09.039
137. She H, Hu Y, Zhou Y, et al. Protective effects of dexmedetomidine on sepsis-induced vascular leakage by alleviating ferroptosis via regulating metabolic reprogramming. *J Inflamm Res*. 2021;14:6765–6782. doi:10.2147/JIR.S340420
138. Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. *Free Radic Biol Med*. 2020;152:175–185. doi:10.1016/j.freeradbiomed.2020.02.027
139. Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature*. 2019;575:7784:688–692. doi:10.1038/s41586-019-1705-2
140. Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. *Redox Biol*. 2019;23:101107. doi:10.1016/j.redox.2019.101107
141. Zou X, Liu C, Huang Z, et al. Inhibition of STEAP1 ameliorates inflammation and ferroptosis of acute lung injury caused by sepsis in LPS-induced human pulmonary microvascular endothelial cells. *Mol Biol Rep*. 2023;50(7):5667–5674. doi:10.1007/s11033-023-08403-7
142. Shen K, Wang X, Wang Y, et al. miR-125b-5p in adipose derived stem cells exosome alleviates pulmonary microvascular endothelial cells ferroptosis via Keap1/Nrf2/GPX4 in sepsis lung injury. *Redox Biol*. 2023;62:102655. doi:10.1016/j.redox.2023.102655
143. Fei Y, Huang X, Ning F, et al. NETs induce ferroptosis of endothelial cells in LPS-ALI through SDC-1/HS and downstream pathways. *Biomed Pharmacother*. 2024;175:116621. doi:10.1016/j.biopha.2024.116621
144. Wang W, Xu R, He P, et al. CircEXOC5 aggravates sepsis-induced acute lung injury by promoting ferroptosis through the IGF2BP2/ATF3 axis. *J Infect Dis*. 2024;229(2):522–534. doi:10.1093/infdis/jiad337B2

145. Wu Z, Xi Q, Zhao Q, et al. GDF11 overexpression alleviates sepsis-induced lung microvascular endothelial barrier damage by activating SIRT1/NOX4 signaling to inhibit ferroptosis. *Shock*. 2024;62(2):245–254. doi:10.1097/SHK.0000000000002391
146. Cadwell K. Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis. *Nat Rev Immunol*. 2016;16(11):661–675. doi:10.1038/nri.2016.100
147. Ren C, Zhang H, Wu TT, Yao YM. Autophagy: a potential therapeutic target for reversing sepsis-Induced immunosuppression. *Front Immunol*. 2017;8:1832. doi:10.3389/fimmu.2017.01832
148. Huang J, Ita M, Zhou H, et al. Autophagy induced by taurolidine protects against polymicrobial sepsis by promoting both host resistance and disease tolerance. *Proc Natl Acad Sci USA*. 2022;119(19):e2121244119. doi:10.1073/pnas.2121244119
149. Gao P, Wu B, Ding Y, Yin B, Gu H. circEXOC5 promotes acute lung injury through the PTBP1/Skp2/Runx2 axis to activate autophagy. *Life Sci Alliance*. 2023;6(1):e202201468. doi:10.26508/lsa.202201468
150. Ding H, Li Y, Chen S, et al. Fisetin ameliorates cognitive impairment by activating mitophagy and suppressing neuroinflammation in rats with sepsis-associated encephalopathy. *CNS Neurosci Ther*. 2022;28(2):247–258. doi:10.1111/cns.13765
151. Jiang T, Liu E, Li Z, et al. SIRT1-Rab7 axis attenuates NLRP3 and STING activation through late endosomal-dependent mitophagy during sepsis-induced acute lung injury. *Int j Surg*. 2024. doi:10.1097/JS9.0000000000001215
152. Mai J, He Q, Liu Y, Hou Y. Hyperoside attenuates sepsis-induced acute lung injury (ALI) through autophagy regulation and inflammation suppression. *Mediators Inflammation*. 2023;2023:1–9. doi:10.1155/2023/1257615
153. Pang R, Dong L, Liu J, Ji X, Zhuang H, Duan M. The study on role of endothelial cell autophagy in rats with sepsis-induced acute kidney injury. *Heliyon*. 2023;9(3):e13796. doi:10.1016/j.heliyon.2023.e13796
154. Wu J, Ma Z, Raman A, et al. APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis. *Immunity*. 2021;54(11):2632–2649.e6. doi:10.1016/j.immuni.2021.10.004
155. Chao CH, Chen HR, Chuang YC, Yeh TM. Macrophage migration inhibitory factor-induced autophagy contributes to thrombin-triggered endothelial hyperpermeability in sepsis. *Shock*. 2018;50(1):103–111. doi:10.1097/SHK.0000000000000976
156. Lu LH, Chao CH, Yeh TM. Inhibition of autophagy protects against sepsis by concurrently attenuating the cytokine storm and vascular leakage. *J Infect*. 2019;78(3):178–186. doi:10.1016/j.jinf.2018.12.003
157. Leonard A, Millar MW, Slavin SA, et al. Critical role of autophagy regulator Beclin1 in endothelial cell inflammation and barrier disruption. *Cell Signal*. 2019;61:120–129. doi:10.1016/j.cellsig.2019.04.013
158. Zhang D, Zhou J, Ye LC, et al. Autophagy maintains the integrity of endothelial barrier in LPS-induced lung injury. *J Cell Physiol*. 2018;233(1):688–698. doi:10.1002/jcp.25928
159. Gerlach H. Agents to reduce cytokine storm. *F1000Res*. 2016;5:2909. doi:10.12688/f1000research.9092.1
160. Tang A, Yu LX, Gao N, Peng HT, Yan S, Zhang G. DI-3-n-butylphthalide improves intestinal microcirculation disorders in septic rats by regulating the PI3K/AKT signaling pathway and autophagy. *Int Immunopharmacol*. 2023;118:110049. doi:10.1016/j.intimp.2023.110049
161. Li Y, Ke J, Peng C, Wu F, Song Y. microRNA-300/NAMPT regulates inflammatory responses through activation of AMPK/mTOR signaling pathway in neonatal sepsis. *Biomed Pharmacother*. 2018;108:271–279. doi:10.1016/j.biopha.2018.08.064
162. Li G, Wang B, Ding X, Zhang X, Tang J, Lin H. Plasma extracellular vesicle delivery of miR-210-3p by targeting ATG7 to promote sepsis-induced acute lung injury by regulating autophagy and activating inflammation. *Exp Mol Med*. 2021;53(7):1180–1191. doi:10.1038/s12276-021-00651-6
163. Zhang H, Zhang X, Ling C, et al. EGFR-TNFR1 pathway in endothelial cell facilitates acute lung injury by NF- κ B/MAPK-mediated inflammation and RIP3-dependent necroptosis. *Int Immunopharmacol*. 2023;117:109902. doi:10.1016/j.intimp.2023.109902
164. Huang WY, Lai YL, Liu KH, et al. TNF α -mediated necroptosis in brain endothelial cells as a potential mechanism of increased seizure susceptibility in mice following systemic inflammation. *J Neuroinflammation*. 2022;19(1):29. doi:10.1186/s12974-022-02406-0
165. Xia W, Pan Z, Zhang H, Zhou Q, Liu Y. ERR α protects against sepsis-induced acute lung injury in rats. *Mol Med*. 2023;29(1):76. doi:10.1186/s10020-023-00670-1
166. Martino E, D'Onofrio N, Balestrieri A, et al. MiR-15b-5p and PCSK9 inhibition reduces lipopolysaccharide-induced endothelial dysfunction by targeting SIRT4. *Cell Mol Biol Lett*. 2023;28(1):66. doi:10.1186/s11658-023-00482-5
167. Zhuo L, Chen X, Sun Y, et al. Rapamycin inhibited pyroptosis and reduced the release of IL-1 β and IL-18 in the septic response. *Biomed Res Int*. 2020;2020:5960375. doi:10.1155/2020/5960375
168. Li Z, Yu Y, Bu Y, et al. QiShenYiQi pills preserve endothelial barrier integrity to mitigate sepsis-induced acute lung injury by inhibiting ferroptosis. *J Ethnopharmacol*. 2024;322:117610. doi:10.1016/j.jep.2023.117610
169. Peng F, Chang W, Sun Q, et al. HGF alleviates septic endothelial injury by inhibiting pyroptosis via the mTOR signalling pathway. *Respir Res*. 2020;21(1):215. doi:10.1186/s12931-020-01480-3